Authors
Xiao, R., Zheng, J., Loponte, H. F. B. R., Ding, Y., Gross-Valle, C., Derks, T. G. J., Horvatovich, P. L., Heiner-Fokkema, M. R., Bakker, B. M., Wolters, J. C., Lageveen-Kammeijer, G. S. M.
Abstract
Glycogen storage disease (GSD) types Ia and Ib are rare inherited metabolic disorders caused by pathogenic variants in G6PC or SLC37A4, respectively. These defects disrupt glucose homeostasis and may affect protein glycosylation. We systematically profiled sera N-glycomes from retrospectively collected GSD Ia (n=17), GSD Ib (n=8), and control (n=21) samples. Derived traits analyses revealed distinct, subtype-specific, and shared glycomic alterations, including shifts from 2,3- to 2,6-sialylation in both subtypes. GSD Ia showed enhanced branching and reduced fucosylation, whereas GSD Ib displayed elevated fucosylation, bisection, and reduced branching. In GSD Ia patients with hepatocellular adenoma/carcinoma (HCA/HCC), further enrichment of oligomannosidic and 2,3-sialylation was observed. Several individual N-glycans showed strong discriminatory performance, supporting their potential as biomarkers for GSD I subtyping and HCA/HCC surveillance. This study provides the first comprehensive characterization of systemic N-glycans in GSD Ia and Ib, revealing glycomic remodeling as a potential biomarker of disease subtypes and tumor progression. Take-home message (synopsis) of the article: Serum/plasma N-glycomic profiling reveals distinct glycosylation signatures in GSD Ia and GSD Ib, including tumor-associated shifts in GSD Ia, highlighting novel biomarkers for disease subtyping and surveillance of hepatic complications.
Preprint server:
bioRxiv
The authors list and abstract were imported from bioRxiv on 24 Oct 2025.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 38
- Comments 0